Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of a position statement by the European Menopause and Andropause Society (EMAS) in the journal Maturitas on the topic of the management of postmenopausal women with vertebral osteoporotic fracture.
Vertebral osteoporotic fracture is an underestimated condition as only about a third of people with the disease seek medical attention. While it may cause acute back pain, the presentation may be insidious with gradual loss of height. Vertebral osteoporotic fractures are associated with significant morbidity, excess mortality as well as being costly to healthcare providers. Also, once a woman has a fracture this increases her risk of further fracture. It is therefore important for healthcare professionals to detect and treat suspected fractures early.
The management of women with osteoporotic vertebral fractures should be provided by a multidisciplinary team. It includes early pain relief and mobilization, spinal support, spinal surgery and long term management of the underlying osteoporosis. Any other underlying pathology, such as cancer, should be sought and treated. Medical treatment of osteoporosis with effective agents such as menopausal hormone therapy, SERMS, bisphosphonates or denosumab, depending on age and concomitant medical conditions, need to be started as soon as possible. It is essential that the women are calcium and vitamin D replete.
These and other recommendations presented in EMAS' position statement are published in the article, "EMAS Position statement: The management of postmenopausal women with vertebral osteoporotic fracture" by Ioannis K. Triantafyllopoulos, Kalliopi Lambropoulou-Adamidou, Cleopatra C. Nacopoulos, Nikolaos A. Papaioannou, Iuliana Ceausu, Herman Depypere, C. Tamer Erel, Faustino R. Pérez-López, Karin Schenck-Gustafsson, Yvonne T. van der Schouw, Tommaso Simoncini, Florence Tremollieres, Margaret Rees and Irene Lambrinoudaki.